(Q43164376)

English

Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma

scientific article published on 12 February 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

1 reference

based on heuristic

inferred from title

tumor progression

1 reference

based on heuristic

inferred from title

7

object named as

Tom Mikkelsen

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

author name string

Richard M Zuniga

1

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Roy Torcuator

2

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Rajan Jain

3

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

John Anderson

4

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Thomas Doyle

5

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Lonni Schultz

6

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

publication date

12 February 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

99

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

237-242

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

https://scigraph.springernature.com/pub.10.1007/s11060-010-0121-0

0 references

Clinical implications of circulating angiogenic factors in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20151176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20151176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20151176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20151176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

1 reference

https://pubmed.ncbi.nlm.nih.gov/20151176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/20151176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Time course of imaging changes of GBM during extended bevacizumab treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20151176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20151176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20151176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20151176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20151176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/20151176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20151176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of angiogenesis in gliomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/20151176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20151176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VEGF as a therapeutic target in cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20151176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20151176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20151176

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-010-0121-0

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43164376&oldid=2070855949"